Cancer is one of the leading causes of morbidity and mortality worldwide, with about 14 million estimated new cases and 8 million deaths annually.1 For solid tumors such as breast cancer, surgical removal remains an essential and vital part of the overall treatment strategy.2 However, the perioperative period is increasingly recognized as a timepoint with the potential to influence patient outcomes profoundly.3 First, the mechanical process of tumor resection and subsequent regenerative processes may promote the recurrence of local residual disease. Second, perioperative immunosuppression may impair the host’s ability to attack circulating tumor cells (CTCs) or distant micrometastases. Third, some drugs administered perioperatively, such as opioids, have been alleged to promote tumor growth in their own right.3 Therefore, theoretically, regional anesthetic strategies, using local anesthetics to reversibly block nerve impulse propagation, seem to be ideally suited to treat perioperative cancer patients. These techniques, among their other effects, decrease the surgical stress response, preserve the patient’s immune system to a greater extent than general anesthesia, and reduce the need for opioids.4,5 In addition to these indirect effects, direct cytotoxic effects of local anesthetics on tumor cells as well as modulation and inhibition of subcellular pathways essential to tumor progression and metastasis have been described experimentally.6 This review will thus aim to outline experimental and clinical evidence of how local anesthetics might be able to interfere with processes important for the pathogenesis of metastasis during the perioperative period and to summarize preclinical and clinical evidence supporting their use leading to a possible better patient outcome. CTCs are released from the primary tumor into the circulation or the lymphatic system and might then be able to form new metastases.7 The number of CTCs can be correlated with the patient outcome and has been established as an independent prognostic factor for survival in metastatic breast, colon, and prostate cancer.8 The concept of CTCs and their contribution to metastasis and therefore a possible worsened outcome was first described in 1963 and has gained more and more attention over the last couple of years.9 Depending on the type of tumor, the stage of the disease and possible prior treatments (eg, neoadjuvant chemotherapy), the number of CTCs that can be detected at a given timepoint during the course of the disease might differ substantially.10–12 However, it has also been demonstrated that there might be a significant increase in the release of CTCs during the perioperative period. For example, patients with pancreatic cancer13 might undergo a successful resection of a primary tumor, but still die from cancer recurrence due to new metastatic sites formed by the CTCs released during surgery.14 Therefore, the perioperative period might be crucial for the individual patient’s outcome and survival. During surgery, the patient’s body faces a phenomenon called the “stress response”: the release of several proinflammatory cytokines, such as interleukins and tumor necrosis factor α (TNFα), leads to a general proinflammatory state associated with the suppression of immune cell function.15,16 NK cells, a lymphocytic subset of the innate immune system,17 are involved in the first line of defense against infected and malignant cells.18,19 In rats, NK cell activity was significantly attenuated by stress and by surgical procedures (laparotomy), which subsequently also led to an increase in the retention of inoculated tumor cells in these animals.20 In humans undergoing surgery for breast, hepatocellular, or pulmonary carcinoma, a reduction of NK cell activity has also been observed.21 The influence of anesthetics on NK cell activity has been studied extensively.